FDA has approved CDK4/6 inhibitors in HER2-negative, ER-positive postmenopausal breast cancer patients, which can block the binding site of cell cycle protein D1 on CDK4/6 thereby inhibiting tumor cell proliferation. This evidence concerns the gene CDK4 and breast carcinoma.